RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Conditions: Systemic Sclerosis; Scleroderma Interventions: Biological: CABA-201 Sponsors: Cabaletta Bio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials